(Q35106125)

6 August 2017

1 reference

title

Bone marrow transplant in Ph+ ALL patients (English)

1 reference

6 August 2017

Avivi I

1

1 reference

6 August 2017

Goldstone AH

series ordinal

2

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

full work available at URL

6 August 2017

https://www.nature.com/articles/1703899

1 reference

https://api.crossref.org/works/10.1038/SJ.BMT.1703899

https://www.nature.com/articles/1703899.pdf

23 December 2023

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1038/SJ.BMT.1703899

Bone Marrow Transplantation

23 December 2023

published in

1 reference

6 August 2017

31

1 reference

6 August 2017

8

1 reference

6 August 2017

623-632

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1703899

6 August 2017

0 references

cites work

Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

Gene-marking to trace origin of relapse after autologous bone-marrow transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

Bax:Bcl-2 ratio modulation by bryostatin 1 and novel antitubulin agents is important for susceptibility to drug induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line, Reh.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

The proteasome: a new target for novel drug therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

7 January 2021

Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

7 January 2021

Induction of graft-versus-leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by pre-emptive donor leukocyte infusions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

7 January 2021

The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

7 January 2021

Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

7 January 2021

In patients with BCR-ABL-positive ALL in CR peripheral blood contains less residual disease than bone marrow: implications for autologous BMT

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

7 January 2021

Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

7 January 2021

Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

7 January 2021

Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

7 January 2021

Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

7 January 2021

Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

7 January 2021

Autologous Transplantation with CD52 Monoclonal Antibody-Purged Marrow for Acute Lymphoblastic Leukemia: Long-Term Follow-Up

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

7 January 2021

Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

7 January 2021

Successful prevention of hematological relapse for a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation by donor leukocyte infusion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

7 January 2021

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703899

7 January 2021

European Cytokine Network

54

11

91

D Blaise

2000

1 reference

https://api.crossref.org/works/10.1038/SJ.BMT.1703899

23 December 2023

58

98

105a

N Jendreyko

2001

1 reference

https://api.crossref.org/works/10.1038/SJ.BMT.1703899

23 December 2023

Identifiers

1 reference

6 August 2017

1 reference